trending Market Intelligence /marketintelligence/en/news-insights/trending/6h7FiVqdeNdVWWaxb8BvBQ2 content esgSubNav
In This List

Kuros Biosciences CFO resigns; company names replacement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kuros Biosciences CFO resigns; company names replacement

Kuros Biosciences AG said Harry Welten will step down as CFO on Feb. 1, 2018, to focus on his board roles and part-time CFO functions in privately held companies.

Welten, who will remain on Kuros' board, will be replaced by Michael Grau as CFO, effective Feb. 1, 2018.

Previously, Grau served as CFO of Proteros Biostructures, a biotech company focusing on enabling lead discovery; Correvio, a Geneva-based hospital specialty pharmaceutical company; and Endosense, a Geneva-based private medical technology company.